Introduction {#s1}
============

Colorectal cancer (CRC) and gastric cancer (GC) are common gastrointestinal cancers. The latest epidemiological data shows that the incidence of CRC ranks 4th in malignant tumors, and the mortality rate ranks 2nd; the incidence and mortality of GC both ranks the 16th in malignant tumors ([@B1]). Symptoms of CRC and GC are occult, most patients are diagnosed until advanced stages. According to statistics from the National Cancer Institute (<https://seer.cancer.gov/statfacts/>), the 5-year survival rate is 64.5% for CRC and 31.0% for GC under current treatment conditions ([@B2]). In recent years, the advent of anti-epidermal growth factor receptor (*EGFR*) monoclonal antibodies (MoAbs), such as cetuximab and panitumumab, have contributed to improving the 5-year survival of CRC patients. The benefits of individual genetic profiling for the selection of therapy have been proven in clinical use. However, the incidence and mortality of CRC and GC remain high.

The main function of anti-*EGFR* MoAbs is to compete with endogenous ligands for binding to *EGFR*, thereby blocking downstream RAS and MAPK signaling pathways, inhibiting proliferation of cancer cells, and prolonging the survival of patients with advanced cancer ([@B3]). *KRAS, NRAS* and *BRAF* are kinases on the RAS-RAF-MAPK signaling pathway. If the RAS and RAF genes are mutated, the mutated protein will not be regulated by the upstream *EGFR* signal and remain in the activated state, continuing to activate the downstream MAPK pathway, leading to cell uncontrolled proliferation and canceration ([@B4]). What\'s worse, mutations in the RAS and RAF genes are independent of each other, and mutations in either of them will lead to activation of the RAS-RAF-MAPK signaling pathway. Meanwhile, *KRAS, NRAS* and *BRAF* are potential tumor-driven genes themselves ([@B5]). Therefore, only patients with wild-type *KRAS, NRAS*, and *BRAF* genes can benefit from anti-*EGFR* targeted therapy ([@B6]--[@B8]), while patients with *KRAS, NRAS*, and *BRAF* mutations are resistant to anti-*EGFR* MoAbs therapy ([@B9]). Detection of *KRAS, NRAS*, and *BRAF* gene mutation status in CRC tissue is a direct and effective method for screening patients for using anti-*EGFR* targeted drugs ([@B10]). The 2017 edition of National Comprehensive Cancer Network (NCCN) recommends that *KRAS, NRAS*, and *BRAF* gene mutations should be identified in primary or metastatic tumors of patients with metastatic colorectal cancer, as a basis for predicting whether or not the patient should be treated with anti-*EGFR* MoAbs ([@B11]). Therefore, the detection of multiple genes such as *KRAS, NRAS*, and *BRAF* can accurately predict the efficacy of anti-*EGFR* MoAbs, thereby realizing individualized targeted therapy.

98.5% of the *KRAS* mutation occurs in codons 12 or 13 of exon 2. The common mutation site of *NRAS* gene is located in exons 2, 3, and 4 ([@B6]). About 81.9% *BRAF* mutations are located at codon 600 with a conversion of valine to glutamic acid (V600E) ([@B4]). Several studies indicated that different mutation types of *KRAS, NRAS*, and *BRAF* gene in colorectal cancer tissues have different biological characteristics and lead to different biological changes, which may have different effects on patients. For example, a growing number of studies have shown that patients with a mutation in codon 13 of the *KRAS* gene may have a poorer prognosis but may significantly benefit from an anti-*EGFR* targeted therapy ([@B12]). However, some other studies have denied this conclusion. Apparently, the effects of different mutations on the biological properties of tumors and the real mechanisms that lead to different outcomes need to be further elucidated. Most of the previous studies focused on the frequencies and prognostic values of *KRAS, NRAS*, and *BRAF* mutations, however, there is still a lack of understanding of the histopathological changes and other related protein expressions changes caused by these mutations. At the same time, the *KRAS, NRAS*, and *BRAF* gene mutation status and the related histopathological changes in GC tissue is still rarely reported.

In the present study, firstly, we detected the common mutation sites of *KRAS, NRAS*, and *BRAF* gene in CRC and GC tissues of 260 patients by amplification-refractory mutation system polymerase chain reaction (ARMS-PCR). Then, we investigated the frequencies and biological characteristics of *KRAS, NRAS*, and *BRAF* mutations. Subsequently, we analyzed the relationship between *KRAS, NRAS*, and *BRAF* mutations and the changes of histopathological features and related protein expressions. In order to better explain the potential effect of *KRAS, NRAS*, and *BRAF* mutations on the efficacy of anti-*EGFR* MoAbs targeted therapy and the prognosis of CRC and GC patients.

Materials and methods {#s2}
=====================

Samples
-------

Two hundred sixty patients (including 86 cases of colon cancer, 140 cases of rectal cancer and 34 cases of gastric cancer) are consecutively collected at the Second Hospital of Jilin University between November 2016 and June 2018. All cases were diagnosed as CRC or GC by two independent pathologists. For each sample, the histopathological sections were stained by hematoxylin-eosin (HE) and immunohistochemistry (IHC) for clinical pathological diagnosis. No patients had accepted preoperative adjuvant treatment. The patients\' information is listed in Table [1](#T1){ref-type="table"}.

###### 

Clinicopathological characteristics of the patients.

  **Factor**               **Colon cancer (*n* = 86), *n* (%)**   **Rectal cancer (*n* = 140), *n* (%)**   **Gastric cancer (*n* = 34), *n* (%)**   **Total (*n* = 260), *n* (%)**
  ------------------------ -------------------------------------- ---------------------------------------- ---------------------------------------- --------------------------------
  **AGE (YEARS)**\'                                                                                                                                 
  Mean ± SD                63.53 ± 11.24                          61.53 ± 10.39                            64.09 ± 8.74                             62.47 ± 10.51
  Median                   64.5 (range, 29--88)                   62 (range, 35--87)                       64 (range, 49--83)                       63 (range, 29--88)
  \<60                     28 (32.6)                              58 (41.4)                                10 (29.4)                                96 (36.9)
  ≥60                      58 (67.4)                              82 (58.6)                                24 (70.6)                                164 (63.1)
  **SEX**                                                                                                                                           
  Male                     51 (59.3)                              99 (70.7)                                26 (76.5)                                176 (67.7)
  Female                   35 (40.7)                              41 (29.3)                                8 (23.5)                                 84 (32.3)
  **HISTOLOGICAL GRADE**                                                                                                                            
  I                        2 (2.3)                                25 (17.9)                                2 (5.9)                                  29 (11.2)
  II                       42 (48.8)                              38 (27.1)                                3 (8.8)                                  83 (31.9)
  III                      40 (46.5)                              77 (55.0)                                12 (35.3)                                129 (49.6)
  IV                       2 (2.3)                                0 (0)                                    17 (50.0)                                19 (7.3)
  **NODAL STATUS**                                                                                                                                  
  Positive                 42 (48.8)                              77 (55.0)                                30 (88.2)                                149 (57.3)
  Negative                 44 (51.2)                              63 (45.0)                                4 (11.8)                                 111 (42.7)

Ethics statement
----------------

The Ethics Committee of the Second Hospital of Jilin University has a detailed understanding of and approved all experimental protocols in this study. This study conforms to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). We informed all participants according to the consent for the use of their specimens, and written consents were obtained from each patient. All involved methods were carried out in accordance with relevant guidelines and regulations of the Ethics Committee of the Second Hospital of Jilin University.

DNA extraction and mutation detection
-------------------------------------

Genomic DNA was extracted from surgically excised fresh solid tumor tissues. The TIANamp Genomic DNA Kit (Tiangen Biotech, Beijing, China) were used according to the manufacturer\'s instructions.

For each sample, mutations of *KRAS* exons 2 (codon 12 and 13) were detected by Human *KRAS* Gene Seven Mutation Detection Kit (YZY Medical Science & Technology Co., Ltd., Wuhan, China); mutations of *NRAS* exons 2 (codon 12 and 13), exons 3 (codon 59 and 61), exons 4 (codon 117 and 146) were detected by Human *NRAS* Gene Mutation Detection Kit (YZY Medical Science & Technology Co., Ltd., Wuhan, China); mutations of *BRAF* exons 15 (codon 600) was detected by Human *BRAF* Gene V600E Mutation Detection Kit (YZY Medical Science & Technology Co., Ltd., Wuhan, China). All operations were strictly performed in accordance with the kit manual. Specifically, diluted 30 ng of total DNA sample to 2 μl, then mixed with 0.2 μl polymerase. The mixture was then added to a tube preloaded with a dual fluorescent probe primer. Real-time quantitative polymerase chain reaction was performed by ABI 7500 Fast Dx (Applied Biosystems Co. Ltd., US) as 37°C for 10 min, 95°C for 5 min, then 40 cycles of 95°C for 15 s and 60°C for 60 s.

IHC staining
------------

All samples were fixed in 4% neutral formaldehyde solution and embedded in paraffin. Tissue block was sliced into 2 μm and dewaxed, hydrated and antigen repaired by PT link (Dako, Agilent Technologies, USA). Specifically, place the slices in the 65°C preheated repair solution, and incubated for 30 min by heating to 90°C, then cooled to 70°C. Subsequently, the slices were washed by PBS. Primary, secondary antibodies and DAB coloring solution were automated incubated by Autostainer Link 48 (Dako, Agilent Technologies, USA). Specifically, incubated with hydrogen peroxide for 10 min, primary antibody for 30 min, and secondary antibody for 20 min in room temperature. Counterstain with hematoxylin, routine dehydration, transparent, and seal.

Statistical analysis
--------------------

Statistical analysis was performed using the SPSS version 21 (SPSS Inc., USA). Categorical variables were compared by the Chi-square or Fisher\'s exact test; quantitative and ordered variables were compared by the Mann-Whitney test. Normally distributed variables were compared by Student\'s *t*-test. The correspondence relationship between mutation status and immunohistochemical marker characteristics were analyzed using Canonical Correlation Analysis and Multiple Correspondence Analysis. *P* \< 0.05 indicate the statistically significantly difference. The Kaplan-Meier (KM) method were used to evaluate the time to diagnosis of survival, recurrence and metastases.

Results {#s3}
=======

Mutation frequencies and distributions
--------------------------------------

### General situation

The distribution of age between *KRAS*/*NRAS*/*BRAF* mutant type (MT) and wild type (WT) was compared by Student\'s *t*-test. Additionally, Chi-square test was amplified to analyze the distribution of different age components (divided into two groups by 60 years old) in *KRAS*/*NRAS*/*BRAF* MT and WT. It can be found that *KRAS*/*NRAS*/*BRAF* mutations were not significantly related to patients\' age (Figure [1](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). When analyzing the relationship between gender and *KRAS*/*NRAS*/*BRAF* mutations, it can be found that the mutation rate of *KRAS* gene in female (48.8%) is significantly higher than that of male (27.8%) (*p* = 0.001). When analyzing the mutation rates of *KRAS, NRAS*, and *BRAF* in different locations, it can be found that *KRAS* gene mutation rate was significantly different in colon cancers (44.2%), rectal cancers (37.1%) and gastric cancers (0%) (*p* \< 0.001). The mutation distribution is shown in Table [2](#T2){ref-type="table"}.

![Age distribution of KRAS/NRAS/BRAF mutant type and wild type patients.](fonc-08-00487-g0001){#F1}

###### 

Histopathological characteristics according to KRAS/NRAS/BRAF mutation status.

                                                   **Total Case**   **KRAS (codon 12/13)**   **NRAS (codon 12/13/59/61/117/146)**   **BRAF (codon 600)**                                                                                                                                                                                           
  ------------------- ---------------------------- ---------------- ------------------------ -------------------------------------- ----------------------------------------------------------------------- --------------- --------------- ----------------------------------------------------------------------- -------------- --------------- ---------------------------------------
  Age                 Mean ± SD                                     63.46 ± 11.43            61.94 ± 9.98                           0.270[^†^](#TN1){ref-type="table-fn"}                                   55.14 ± 10.29   62.67 ± 10.46   0.062[^†^](#TN1){ref-type="table-fn"}                                   65.00 ± 5.57   62.42 ± 10.58   0.587[^†^](#TN1){ref-type="table-fn"}
                      \<60                         96               31                       65                                     0.547[^‡^](#TN2){ref-type="table-fn"}                                   4               92              0.216[^‡^](#TN2){ref-type="table-fn"}                                   1              95              0.428[^‡^](#TN2){ref-type="table-fn"}
                      ≥60                          164              59                       105                                                                                                            3               161                                                                                     4              160             
  Sex                 Male                         176              49                       127                                    **0.001**[^‡^](#TN2){ref-type="table-fn"}                               5               171             0.830[^‡^](#TN2){ref-type="table-fn"}                                   2              174             0.181[^‡^](#TN2){ref-type="table-fn"}
                      Female                       84               41                       43                                                                                                             2               82                                                                                      3              81              
  Location            Colon cancer                 86               38                       48                                     **0.000**[^‡^](#TN2){ref-type="table-fn"}                               1               85              0.216[^‡^](#TN2){ref-type="table-fn"}                                   3              83              0.303[^‡^](#TN2){ref-type="table-fn"}
                      Rectal cancer                140              52                       88                                     0.294[^‡^](#TN2){ref-type="table-fn"}[^¶^](#TN4){ref-type="table-fn"}   6               134             0.188[^‡^](#TN2){ref-type="table-fn"}[^¶^](#TN4){ref-type="table-fn"}   1              139             0.125[^‡^](#TN2){ref-type="table-fn"}
                      Gastric cancer               34               0                        34                                                                                                             0               34                                                                                      1              33              
  Histological type   Adenocarcinoma               230              79                       151                                    **0.033**[^‡^](#TN2){ref-type="table-fn"}                               7               223             0.919[^‡^](#TN2){ref-type="table-fn"}                                   5              225             0.964[^‡^](#TN2){ref-type="table-fn"}
                      Mucinous adenocarcinoma      15               9                        6                                                                                                              0               15                                                                                      0              15              
                      Low adhesion carcinoma       11               0                        11                                                                                                             0               11                                                                                      0              11              
                      Signet-ring cell carcinoma   2                1                        1                                                                                                              0               2                                                                                       0              2               
                      Squamous cell carcinoma      2                1                        1                                                                                                              0               2                                                                                       0              2               
  Differentiation     Well                         6                3                        3                                      **0.036**[^§^](#TN3){ref-type="table-fn"}                               0               6               0.506[^§^](#TN3){ref-type="table-fn"}                                   0              6               0.503[^§^](#TN3){ref-type="table-fn"}
                      Moderate                     182              69                       113                                                                                                            6               176                                                                                     3              179             
                      Poor                         72               18                       54                                                                                                             1               71                                                                                      2              70              
  TNM stage           I                            29               8                        21                                     0.454[^§^](#TN3){ref-type="table-fn"}                                   0               29              0.585[^§^](#TN3){ref-type="table-fn"}                                   0              29              0.893[^§^](#TN3){ref-type="table-fn"}
                      II                           83               31                       52                                                                                                             4               79                                                                                      2              81              
                      III                          129              51                       78                                                                                                             3               126                                                                                     3              126             
                      IV                           19               0                        19                                                                                                             0               19                                                                                      0              19              
  T                   T1                           4                1                        3                                      0.500[^§^](#TN3){ref-type="table-fn"}                                   0               4               0.640[^§^](#TN3){ref-type="table-fn"}                                   0              4               0.824[^§^](#TN3){ref-type="table-fn"}
                      T2                           35               10                       25                                                                                                             1               34                                                                                      1              34              
                      T3                           195              70                       125                                                                                                            6               189                                                                                     3              192             
                      T4                           26               9                        17                                                                                                             0               26                                                                                      1              25              
  N                   Negative                     111              39                       72                                     0.879[^‡^](#TN2){ref-type="table-fn"}                                   4               107             0.433[^‡^](#TN2){ref-type="table-fn"}                                   2              109             0.902[^‡^](#TN2){ref-type="table-fn"}
                      Positive                     149              51                       98                                                                                                             3               146                                                                                     3              146             

*t-test*.

*Chi-square test*.

*Mann-Whitney test*.

*Comparison between colon cancer and rectal cancer*.

*Bold values means P \< 0.05, which indicate the statistically significantly difference*.

### Colon cancer

The average age of colon cancer patients was 63.53 ± 11.24 (Table [1](#T1){ref-type="table"}). *KRAS*/*NRAS*/*BRAF* mutations were not significantly related to patients\' age analyzed by Student\'s *t*-test or gender analyzed by Chi-square test in colon cancer. *KRAS* mutations were detected in 38 out of 86 (44.2%) colon cancer samples (Table [2](#T2){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}), of which 28 (73.7%) samples had mutations in codon 12 and 10 (26.3%) samples had mutations in codon 13 (Table [3](#T3){ref-type="table"}). Among mutations in *KRAS* codon 12, the main mutant type was 12ASP (34.2%), followed by 12VAL (21.1%) (Table [3](#T3){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}). *KRAS* mutations occurred in all 7 sites included in this study. In contrast, *NRAS* had a lower mutation rate. *NRAS* mutations were detected in 1 out of 86 (1.2%) colon cancer samples (Table [2](#T2){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}). This mutation occurred in exon 3 codon 61 and the mutant type was Q61-Mu (Table [3](#T3){ref-type="table"}). *BRAF* exon 15 codon 600 600Glu mutation was detected in 3 out of 86 (3.5%) colon cancer samples (Table [2](#T2){ref-type="table"}, Figure [2A](#F2){ref-type="fig"}).

![The mutation distribution of KRAS/NRAS/BRAF in **(A)** colon cancer, **(B)** rectal cancer, and **(C)** gastric cancer.](fonc-08-00487-g0002){#F2}

###### 

Frequency and distribution of KRAS/NRAS/BRAF mutations.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Gene**   **Exon**   **Codon**   **Mutation name**   **Amino acid**   **Nucleotide**   **COSMIC ID**   **Case**, ***n*** **(%)**                           
  ---------- ---------- ----------- ------------------- ---------------- ---------------- --------------- --------------------------- ----------- ----------- -----------
  KRAS       2          12          12CYS               G12C             GGT\>TGT         516             1 (2.6)                     3 (5.7)     0 (0)       4 (4.4)

                                    12SER               G12S             GGT\>AGT         517             3 (7.9)                     3 (5.7)     0 (0)       6 (6.6)

                                    12ARG               G12R             GGT\>CGT         518             1 (2.6)                     1 (1.9)     0 (0)       2 (2.2)

                                    12VAL               G12V             GGT\>GTT         520             8 (21.1)                    13 (24.5)   0 (0)       21 (23.1)

                                    12ASP               G12D             GGT\>GAT         521             13 (34.2)                   23 (43.4)   0 (0)       36 (39.6)

                                    12ALA               G12A             GGT\>GCT         522             2 (5.3)                     1 (1.9)     0 (0)       3 (3.3)

                        13          13ASP               G13D             GGC\>GAC         532             10 (26.3)                   9 (17.0)    0 (0)       19 (20.9)

  NRAS       2          12          G12-Mu              G12D             GGT\>GAT         564             0 (0)                       3 (50.0)    0 (0)       3 (42.9)

                        13          G13-Mu              G13R\            GGT\>CGT\        569\            0 (0)                       2 (33.3)    0 (0)       2 (28.6)
                                                        G13D\            GGT\>GAT\        573\                                                                
                                                        G13V             GGT\>GTT         574                                                                 

             3          59          A59-Mu              A59D             GCT\>GAT         253327          0 (0)                       0 (0)       0 (0)       0 (0)

                        61          Q61-Mu              Q61R             CAA\>CGA         584             1 (100.0)                   1 (1.67)    0 (0)       2 (28.6)

             4          117         K117-Mu             K117N\           AAG\>AAC\        /\              0 (0)                       0 (0)       0 (0)       0 (0)
                                                        K117N            AAG\>AAT         /                                                                   

                        146         A146-Mu             A146T            GCC\>ACC         1237325         0 (0)                       0 (0)       0 (0)       0 (0)

  BRAF       15         600         600Glu              V600E            CTC\>GAG         476             3 (100.0)                   1 (100.0)   1 (100.0)   5 (100.0)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Rectal cancer

The average age of rectal cancer patients was 61.53 ± 10.39 (Table [1](#T1){ref-type="table"}). *KRAS*/*NRAS*/*BRAF* mutations were not significantly related to patients\' age analyzed by Student\'s *t*-test in rectal cancer. The mutation rate of *KRAS* gene in female (53.7%) is significantly higher than that of male (30.3%) (*p* = 0.012) analyzed by Chi-square test in rectal cancer. *KRAS* mutations were detected in 52 out of 140 (37.1%) rectal cancer samples (Table [2](#T2){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}), of which 43 (30.7%) samples had mutations in codon 12 and 9 (6.4%) samples had mutations in codon 13 (Table [3](#T3){ref-type="table"}). Among mutations in *KRAS* codon 12, the main mutant type was 12ASP (16.4%), followed by 12VAL (9.3%) (Table [3](#T3){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}). *KRAS* mutations occurred in all 7 sites included in this study. It is worth noting that, there is one sample harbored both 12ASP and 12SER mutation. *NRAS* mutations were detected in 6 out of 140 (4.3%) rectal cancer samples (Table [2](#T2){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}), of which 3 (2.1%) samples had mutations in exon 2 codon 12, 2 (1.4%) samples had mutations in exon 2 codon 13, and 1 (0.7%) sample had mutations in exon 3 codon 61 (Table [3](#T3){ref-type="table"}). None mutation was detected in *NRAS* exon 3 codon 59, exon 4 codon 117 and 146 in this study. *BRAF* exon 15 codon 600 600Glu mutation was detected in 1 out of 140 (0.7%) rectal cancer samples (Table [2](#T2){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}).

### Gastric cancer

The average age of gastric cancer patients was 64.09 ± 8.74 (Table [1](#T1){ref-type="table"}). *KRAS*/*NRAS*/*BRAF* mutations were not significantly related to patients\' age analyzed by Student\'s *t*-test or gender analyzed by Chi-square test in gastric cancer. Compared with colon cancer and rectal cancer, *KRAS* and *NRAS* have a lower mutation rate in gastric cancer. In all 34 gastric cancer samples, neither *KRAS* nor *NRAS* mutation was detected, and only 1 sample (2.9%) was detected to have a mutation in *BRAF* exon 15 codon 600 600Glu (Table [2](#T2){ref-type="table"}, Table [3](#T3){ref-type="table"}, Figure [2C](#F2){ref-type="fig"}).

Histopathological characteristics of mutations
----------------------------------------------

### Histological type

There were 5 histological types (adenocarcinoma, mucinous adenocarcinoma, low adhesion carcinoma, signet-ring cell carcinoma, squamous cell carcinoma) contained in the 260 investigated tumor samples. The mutation rate of *KRAS* was significantly different among the five histological types (*p* = 0.033). Among the five histological types, the mutation rates of *KRAS* were 34.3% in adenocarcinoma, 60.0% in mucinous adenocarcinoma, 0% in low adhesion carcinoma, 50% in signet-ring cell carcinoma, and 50% in squamous cell carcinoma, respectively. *NRAS* and *BRAF* mutations were only detected in 3.0 and 2.2% of adenocarcinomas, but not detected in other histological types. The mutation distribution is shown in Table [2](#T2){ref-type="table"}.

### Differentiation and staging

*KRAS* mutation rate was significantly different in different degrees of tissue differentiation (*p* = 0.036). The mutation rate was 50.0% in well differentiated cancers, 37.9% in moderate differentiated cancers, and 25.0% in poor differentiated cancers. There was no significant correlation between *KRAS*/*NRAS*/*BRAF* mutations and TNM stage, tumor infiltration depth, and lymph node metastasis. The mutation distribution is shown in Table [2](#T2){ref-type="table"}.

### IHC characteristics of mutations

IHC plays an important role in clinical pathology diagnosis. In the diagnostic process of CRC, BRAF (V600E), PMS2, EGFR, CDX2, CD34, Ki67, P53, MLH1, MSH6, and MSH2 are the most commonly used immunohistochemical markers for pathological typing, differential diagnosis of benign and malignant, and prognosis. Since only one sample was detected to have a mutation in BRAF in all 34 gastric cancer samples, we only investigated the IHC characteristics in colon cancers and rectal cancers.

Interestingly, mutations in the *BRAF* gene (1.77%) were not completely consistent with the IHC results of BRAF (V600E) (4.11%), but their correspondence is significant (*p* = 0.004). Moreover, there was a significant difference in the expression of EGFR between the *NRAS* MT and WT (*p* = 0.049); and there was a significant difference in the expression of MLH1 between the *BRAF* MT and WT (*p* = 0.004) (Table [4](#T4){ref-type="table"}). When analyzing colon and rectal cancers separately, the results were similar. There was a significant difference in the expression of *BRAF* between the BRAF (V600E) MT and WT (*p* = 0.008) in colon cancers; and there was a significant difference in the expression of EGFR between the *NRAS* MT and WT (*p* = 0.021) in rectal cancers (Tables [S1](#SM2){ref-type="supplementary-material"}, [S2](#SM3){ref-type="supplementary-material"}). The representative IHC images for the markers were presented in Figure [S1](#SM1){ref-type="supplementary-material"}.

###### 

Immunohistochemistry characteristics according to KRAS/NRAS/BRAF mutation status in CRC.

                                         **Total Case**   **KRAS (codon 12/13)**   **NRAS (codon 12/13/59/61/117/146)**   **BRAF (codon 600)**                                                                                    
  -------------- ----------------------- ---------------- ------------------------ -------------------------------------- --------------------------------------- --- ----- ------------------------------------------- --- ----- -------------------------------------------
  BRAF (V600E)   Positive                9                3                        6                                      0.710[^†^](#TN5){ref-type="table-fn"}   0   9     1.000[^‡^](#TN6){ref-type="table-fn"}       2   7     **0.004**[^‡^](#TN6){ref-type="table-fn"}
                 Negative                210              83                       127                                                                            7   203                                               1   209   
                 Missing                 7                4                        3                                                                              0   7                                                 1   6     
  PMS2           Positive                216              84                       132                                    0.832[^†^](#TN5){ref-type="table-fn"}   7   209   1.000[^‡^](#TN6){ref-type="table-fn"}       2   214   0.092[^‡^](#TN6){ref-type="table-fn"}
                 Negative                7                3                        4                                                                              0   6                                                 1   6     
                 Missing                 3                3                        0                                                                              0   3                                                 1   2     
  EGFR           Positive                97               38                       59                                     0.503[^§^](#TN7){ref-type="table-fn"}   5   92    **0.049**[^§^](#TN7){ref-type="table-fn"}   0   97    0.468[^§^](#TN7){ref-type="table-fn"}
                 Weakly positive         74               26                       48                                                                             1   73                                                3   71    
                 Negative                48               23                       25                                                                             0   48                                                0   48    
                 Missing                 7                3                        4                                                                              1   6                                                 1   6     
  CDX2           Positive                219              86                       133                                    0.663[^†^](#TN5){ref-type="table-fn"}   7   212   1.000[^‡^](#TN6){ref-type="table-fn"}       3   216   1.000[^‡^](#TN6){ref-type="table-fn"}
                 Partially positive      4                2                        2                                                                              0   4                                                 0   4     
                 Missing                 3                2                        1                                                                              0   3                                                 0   3     
  CD34           Positive                29               16                       13                                     0.604[^§^](#TN7){ref-type="table-fn"}   0   29    0.800[^§^](#TN7){ref-type="table-fn"}       1   28    0.384[^§^](#TN7){ref-type="table-fn"}
                 Vessel positive         42               12                       30                                                                             3   39                                                1   41    
                 Negative                92               37                       55                                                                             2   90                                                1   91    
                 Missing                 63               25                       38                                                                             2   61                                                1   62    
  Ki67           Positive rate ≥90%      75               24                       51                                     0.189[^§^](#TN7){ref-type="table-fn"}   4   71    0.257[^§^](#TN7){ref-type="table-fn"}       0   75    0.626[^§^](#TN7){ref-type="table-fn"}
                 Positive rate 80\~90%   69               29                       40                                                                             1   68                                                2   67    
                 Positive rate 70\~80%   47               23                       24                                                                             2   43                                                1   46    
                 Positive rate 60\~70%   23               9                        14                                                                             0   23                                                0   23    
                 Positive rate 50\~60%   6                2                        4                                                                              0   6                                                 0   6     
                 Positive rate \<50%     3                1                        2                                                                              0   3                                                 0   3     
                 Missing                 3                2                        1                                                                              0   3                                                 1   2     
  P53            Positive rate ≥90%      90               32                       58                                     0.883[^§^](#TN7){ref-type="table-fn"}   4   86    0.540[^§^](#TN7){ref-type="table-fn"}       0   90    0.067[^§^](#TN7){ref-type="table-fn"}
                 Positive rate 80\~90%   17               10                       7                                                                              0   17                                                0   17    
                 Positive rate 70\~80%   7                5                        2                                                                              0   7                                                 0   7     
                 Positive rate 60\~70%   3                1                        2                                                                              0   3                                                 0   3     
                 Positive rate 50\~60%   5                3                        2                                                                              1   4                                                 0   5     
                 Positive rate \<50%     36               14                       22                                                                             0   36                                                2   34    
                 Negative                64               22                       42                                                                             2   62                                                1   63    
                 Missing                 4                3                        1                                                                              0   4                                                 1   3     
  MLH1           Positive                193              74                       119                                    0.431[^§^](#TN7){ref-type="table-fn"}   6   187   0.947[^§^](#TN7){ref-type="table-fn"}       1   192   **0.004**[^§^](#TN7){ref-type="table-fn"}
                 Partially positive      23               8                        15                                                                             1   22                                                1   22    
                 Negative                6                5                        1                                                                              0   6                                                 1   5     
                 Missing                 4                3                        1                                                                              0   4                                                 1   3     
  MSH6           Positive                193              74                       119                                    0.511[^§^](#TN7){ref-type="table-fn"}   6   187   0.951[^§^](#TN7){ref-type="table-fn"}       3   190   0.501[^§^](#TN7){ref-type="table-fn"}
                 Partially positive      22               10                       12                                                                             1   21                                                0   22    
                 Negative                7                3                        4                                                                              0   7                                                 0   7     
                 Missing                 4                3                        1                                                                              0   4                                                 1   3     
  MSH2           Positive                202              80                       122                                    0.655[^§^](#TN7){ref-type="table-fn"}   6   196   0.634[^§^](#TN7){ref-type="table-fn"}       2   200   0.103[^§^](#TN7){ref-type="table-fn"}
                 Partially positive      17               7                        10                                                                             1   16                                                0   17    
                 Negative                3                0                        3                                                                              0   3                                                 1   2     
                 Missing                 4                3                        1                                                                              0   4                                                 1   3     

*Chi-square test*.

*Fisher\'s exact test*.

*Mann-Whitney test*.

*Bold values means P \< 0.05, which indicate the statistically significantly difference*.

Of particular concern is the sample with double mutation sites on *KRAS*, and the immunohistochemistry results are as follows: BRAF (V600E) (--), PMS2 (+), EGFR (+), CDX2 (+), CD34 (--), Ki67 (positive rate 70%), P53 (--), MLH1 (+), MSH6 (+), MSH2 (+).

### Correspondence between mutations and immunohistochemical markers

In order to further explore the correlation between *KRAS*/*NRAS*/*BRAF* mutation status and IHC characteristics in CRC, Canonical Correlation Analysis and Multiple Correspondence Analysis were performed. The Canonical Correlation Analysis results showed that there is a strong correlation between mutation status and IHC characteristics (canonical correlation coefficient is 0.544). Among them, *BRAF* mutation status had a great influence on the mutation status (canonical correlation coefficient is 0.995); BRAF (V600E) expression level had a great influence on the IHC characteristics (canonical correlation coefficient is 0.711), followed by MSH2 (canonical correlation coefficient is −0.547) and MLH1 (canonical correlation coefficient is −0.500). The canonical correlation analysis structural diagram is shown in Figure [3A](#F3){ref-type="fig"}. The Multiple Correspondence Analysis results showed that there is a strong correspondence between BRAF mutation status and BRAF (V600E) expression level, which is theoretically obvious (Figure [3B](#F3){ref-type="fig"}). If the factor of BRAF (V600E) expression level is excluded and re-analyzed, the results showed that the *KRAS* mutation status had a certain relationship with the expression of P53, Ki67, CDX2, and MSH6; the *NRAS* mutation status had a certain relationship with the expression of EGFR; and the *BRAF* mutation status had a certain relationship with the expression of CD34 (Figure [3C](#F3){ref-type="fig"}).

![The correlation between KRAS/NRAS/BRAF mutation status and IHC characteristics in CRC. **(A)** The result of Canonical Correlation Analysis. **(B)** The result of Multiple Correspondence Analysis. **(C)** The result of Multiple Correspondence Analysis without the factor of BRAF (V600E) expression level.](fonc-08-00487-g0003){#F3}

Correspondence between mutations and prognosis
----------------------------------------------

Since the sampling period of this study is only 19 months, it is difficult to accurately reflect the correspondence between gene mutation and prognosis. Therefore, we only summarized the prognosis information of patients up to the present stage. According to the type of mutation, the correspondences between mutation and survival, recurrence and metastasis were analyzed separately. No significant difference was found between mutant type and wild type patients. The correspondence between mutations and survival was shown in Figure [4A](#F4){ref-type="fig"}, the correspondence between mutations and recurrence was shown in Figure [4B](#F4){ref-type="fig"}, the correspondence between mutations and metastasis was shown in Figure [4C](#F4){ref-type="fig"}.

![The correspondence between mutations and prognosis. **(A)** The correspondence between mutations and survival. **(B)** The correspondence between mutations and recurrence. **(C)** The correspondence between mutations and metastasis.](fonc-08-00487-g0004){#F4}

Discussion {#s4}
==========

In this study, we investigated the mutation status of *KRAS* (exons 2, codon 12/13), *NRAS* (exons 2/3/4, codon 12/13/59/61/117/146) and *BRAF* (exons 15, codon 600) in 260 patients, including 86 cases of colon cancer, 140 cases of rectal cancer and 34 cases of gastric cancer. The results showed that *KRAS* mutations were detected in 44.2% colon cancer, 37.1% rectal cancer and none in gastric cancer; *NRAS* mutations were detected in 1.2% colon cancer, 4.3% rectal cancer and none in gastric cancer; *BRAF* mutations were detected in 3.5% colon cancer, 0.7% rectal cancer, and 2.9% in gastric cancer.

The mutation rate of *KRAS* gene in female (48.8%) is significantly higher than that of male (27.8%). *KRAS* gene mutation rate was significantly different in colon cancers (44.2%), rectal cancers (37.1%) and gastric cancers (0%), however, when colon cancer and rectal cancer were compared alone, the difference was not significant.

Compared with the previous studies (Table [5](#T5){ref-type="table"}), the mutation rate of *KRAS* in CRC reported in our study was consistent with that reported by Douillard et al. ([@B6]) and Gao et al. ([@B25]), who also focused on exons 2, codon 12/13. Guo et al. ([@B13]) believed that the mutation rate of *KRAS* was as high as 52.7%. This conclusion may be because they included more genetic loci into the study (exons 2/3/4, codons 12/13/59/61/117/146/147). Compared to the mutation rate of KRAS, there are fewer studies focusing on the mutation rate of *NRAS*. The mutation rate of *NRAS* in CRC obtained in this study was in the midstream position compared to other reports ([@B4], [@B6], [@B13], [@B14], [@B16]). Vaughn et al showed that the mutation rate of *NRAS* in Americans was only 1.2% ([@B24]). We measured a low mutation rate of *BRAF* in CRC. This result is consistent with the research on Chinese carried by Shen et al. ([@B27]). In the study of Mao et al. ([@B20]), the *BRAF* mutation rate reached a staggering 25.4%, much higher than other reports. However, the sample size in that study was only 69 cases, and its representativeness was questionable. By comparison, it can be found that the mutation rate of these three genes is not significantly different between Asians and Europeans.

###### 

Studies on mutation status of KRAS, NRAS and BRAF in CRC.

  **Reference (year)**       **Sample size**   **Method**                                    **Mutation frequencies**                              **Region**                                                                         
  -------------------------- ----------------- --------------------------------------------- ----------------------------------------------------- ------------------------------------------------ --------------------------------- --------------------------
  This study                 226               ARMS-PCR                                      39.82% (exons 2, codon 12/13)                         3.10% (exons 2/3/4, codon 12/13/59/61/117/146)   1.77% (exons 15, codon 600)       China
  Guo F, et al. ([@B13])     353               Direct sequencing                             52.7% (exons 2/3/4, codons 12/13/59/61/117/146/147)   3.4% (exons 2/3, codons 12/13/60/61)             4.5% (exons 15, codons 600/601)   China
  Zhang et al. ([@B14])      1110              ARMS-PCR                                      45.4% (exons 2/3/4, codons 12/13/61/117/146)          3.9% (exons 2/3/4, codon 12/13/61/146)           3.1% (exon 15, codon 600)         China
  Tong et al. ([@B15])       1506              Direct sequencing                             44.5% (exons 2/3/4, codons 12/13/61/146)                                                                                                 Hong Kong, China
  Douillard et al. ([@B6])   1183              Direct sequencing                             40.1% (exons 2, codons 12/13)                         4.1% (exons 2/3/4, codon 12/13/61/117/146)       4.5% (exon 15, codon 600)         France
  Shen et al. ([@B16])       676               Direct sequencing                             35.9% (exons 2/3, codons 12/13/61)                    4.19% (exons 2/3, codons 12/13/61)               6.96% (exon 11/15)                China
  Pu et al. ([@B17])         115               Direct sequencing                             32.2% (exons 2, codons 12/13)                                                                          3.5% (exons 15, codon 600)        China
  Wang et al. ([@B18])       574               Direct sequencing                             34.2% (exons 2/3, codons 12/13/61)                                                                                                       China
  Chang et al. ([@B19])      165               High-resolution melting                       36.97% (exons 2/3, codons 12/13/61                                                                     4.24% (exons 15, codon 600)       Taiwan, China
  Mao et al. ([@B20])        69                Direct sequencing                             43.9% (exons 2, codons 12/13/14)                                                                       25.4% (exons 15, codon 600)       China
  Hsieh et al. ([@B21])      182               Direct sequencing & high-resolution melting   33.5% (exons 2, codons 12/13)                                                                          1.1% (exons 15, codon 600)        Taiwan, China
  Li et al. ([@B22])         78                Direct sequencing                             33.3% (exons 2, codons 12/13)                                                                                                            China
  Yokota et al. ([@B23])     229               Cycleave PCR                                  34.5% (exons 2/3, codons 12/13/61)                                                                     6.5% (exon 15, codon 600)         Japan
  Vaughn et al. ([@B24])     2121              Pyrosequencing                                42.4% (exons 2, codons 12/13)                         1.2% (exons 2/3, codons 12/13/61)                3.7% (exon 15, codon 600)         US
  Gao et al. ([@B25])        273               Direct sequencing                             38.5% (exons 2, codon 12/13)                                                                           5.1% (exon 15, codon 600)         China
  Li et al. ([@B26])         200               Pyrosequencing                                31.5% (exon 2, codon 12/13)                                                                            7.0% (exons 15, codon 600)        China
  Shen et al. ([@B27])       118               Pyrosequencing                                34.7% (exons 2/3, codons 12/13/61)                                                                     1.7% (exons 15, codon 600)        China
  Liou et al. ([@B28])       314               Direct sequencing                             20.7% (exons 2/3, codons 12/13/61)                                                                     3.8% (exon 11/15)                 Taiwan, China
  De Roock et al. ([@B4])    1022              Mass spectrometry genotyping                  40.0% (exons 2/3, codons 12/13/61/146)                2.6% (exons 2/3, codons 12/13/61)                4.7% (exon 15, codon 594/600)     seven European countries

There are many reasons for the different mutation rate results. In addition to the influence of the sample size, different mutation sites included in the study will result in different mutation rates. *KRAS* mutations occur 98.5% in exon 2 at codons 12 and 13. The common mutation site of *NRAS* gene is located in exons 2, 3, and 4. About 81.9% *BRAF* mutations are located at codon 600. Therefore, in this study we focused our attention on the mutations at these sites. Another factor that may affect the outcome of the mutation rate is the detection method. Direct sequencing is the most widely used method for mutation detection ([@B15], [@B17], [@B18], [@B22], [@B28]). It is the gold standard for mutation detection, but it is limited by sensitivity, and only mutations with a mutational heterogeneity more than 10% can be detected. Besides, pyrosequencing ([@B24], [@B26], [@B27]), high-resolution melting ([@B19], [@B21]), ARMS-PCR([@B14]), cycleave PCR([@B23]) and mass spectrometry genotyping ([@B4]) are also used for the detection of mutations. In this study we applied two-color fluorescent probe ARMS-PCR. This method is more sensitive than direct sequencing, as little as 1% of heterogeneous mutations in tumor tissue can be detected. The type of sample to be tested may also have a certain effect on the mutation rate results. In this study, fresh tissue without being fixed by paraformaldehyde was used to avoid DNA damage during the fixation process.

The mutation rate of *KRAS* was significantly different in different histological types, *NRAS* and *BRAF* mutations were only detected in adenocarcinomas. Furthermore, we found that *KRAS* gene mutation rate was significantly different in different degrees of tissue differentiation, but not significantly associated with TNM stage. *KRAS* mutation rate increased with the higher degree of differentiation. These results were a little different from those reported by Guo et al. ([@B13]), who termed *KRAS* mutations had no significant correlation with clinicopathological characteristics.

None of the previous studies investigated the association between *KRAS*/*NRAS*/*BRAF* mutations and IHC characteristics in CRCs. In our study, we investigated the association between *KRAS*/*NRAS*/*BRAF* mutations and commonly used immunohistochemical markers, including BRAF (V600E), PMS2, EGFR, CDX2, CD34, Ki67, P53, MLH1, MSH6, and MSH2. We were surprised to find that the mutations in *BRAF* gene were not completely consistent with the IHC results of BRAF (V600E), the mutation rate of *BRAF* detected by ARMS-PCR (1.77%) was significantly lower than that by IHC (4.11%). Molecular testing is the gold standard for genetic mutation detection. Although many studies have shown that IHC has a good detection effect on BRAF V600E mutations ([@B29]--[@B32]), but there will still be a part of false positive results ([@B33], [@B34]). Ballester et al. ([@B35]) suggested that the highly sensitive molecular assays remain the gold standard for BRAF mutation analysis in paraffin-embedded lesions. Ehsani et al. ([@B36]) used IHC to detect BRAF mutations in metastatic malignant melanoma with a false positive rate of 32%. We suggest that if the purpose of detecting *BRAF* mutations is to guide anti-*EGFR* targeted therapy, genetic testing will benefit more patients rather than IHC. Moreover, we also found that there was a significant difference in the expression of EGFR between the *NRAS* MT and WT; and there was a significant difference in the expression of MLH1 between the *BRAF* MT and WT. Parsons et al. ([@B37]) reported that tumor *BRAF* mutation, and MLH1 promoter "C region" methylation specifically, are strong predictors of negative MMR mutation status in CRCs. Farchoukh et al. ([@B38]) also found that although the presence of the BRAF mutation is indicative of a sporadic cancer, up to 30--50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a *BRAF* mutation. Some similar studies have also shown that *BRAF* mutation is closely linked with MLH1 promoter hypermethylation and DNA mismatch repair (MMR) gene mutations, but its specific mechanism needs further study ([@B39]).

Furthermore, we employed Canonical Correlation Analysis and Multiple Correspondence Analysis to further explore the correlation between *KRAS*/*NRAS*/*BRAF* mutation status and IHC characteristics in CRC. The results indicated that the *KRAS* mutation status had a certain relationship with the expression of P53, Ki67, CDX2, and MSH6; the *NRAS* mutation status had a certain relationship with the expression of EGFR; and the *BRAF* mutation status had a certain relationship with the expression of CD34. There are few direct reports of correlation studies between these genes. We hypothesize that since *KRAS, NRAS*, and *BRAF* are potential tumor-driven genes, their mutation may have some synergistic or inhibitory effects on the expression of genes such as P53, Ki67, CDX2, MSH6, and CD34.

There are few studies on the mutations rate of *KRAS*/*NRAS*/*BRAF* in gastric cancer. And gastric cancer patients benefit little from anti-*EGFR* MoAbs targeted therapy. Compared with colon cancer rectal cancer, *KRAS*/*NRAS*/*BRAF* have a lower mutation rate in gastric cancer, furthermore, there is no consistent conclusion on the role of *KRAS*/*NRAS*/*BRAF* mutations in gastric cancer ([@B40]--[@B43]). In this study we found 1 out of 34 gastric cancer cases with *BRAF* mutation. No *KRAS* or *NRAS* mutation was found in gastric cancer in this study. Here we provide these data for further research by peers.

Since the sampling period of this study is between November 2016 and June 2018, it is difficult to accurately reflect the correspondence between gene mutation and prognosis. Therefore, we only summarized the prognosis information of patients up to the present stage. We will continue to follow this group of patients in subsequent studies to delve into the effects of *KRAS*/*NRAS*/*BRAF* mutation on prognosis.

The limitations of our study are its relatively small sample size, and lack of follow-up time which are important for risk assessment of malignant tumor. *NRAS* and *BRAF* mutation frequency was too low to analyze its mutation subgroups. The specific mechanism and clinical significance of the relationship between *KRAS*/*NRAS*/*BRAF* mutation and IHC status still need further experiments to confirm.

In this study, we systematically described and statistically analyzed the frequencies and distributions of *KRAS*/*NRAS*/*BRAF* genetic mutation status and their relationship with IHC in 260 cases with colorectal cancer or gastric cancer through retrospective analysis. Based on the analysis results, we draw the following conclusions: (1) *KRAS* mutations were detected in 44.2% colon cancer, 37.1% rectal cancer and none in gastric cancer; *NRAS* mutations were detected in 1.2% colon cancer, 4.3% rectal cancer and none in gastric cancer; *BRAF* mutations were detected in 3.5% colon cancer, 0.7% rectal cancer and 2.9% in gastric cancer; (2) the mutation rate of *KRAS* in female (48.8%) was significantly higher than that of male (27.8%); (3) the mutation rate increased with the higher degree of differentiation; (4) the mutation rate of *BRAF* detected by ARMS-PCR (1.77%) was significantly lower than that by IHC (4.11%); (5) the *KRAS*/*NRAS*/*BRAF* mutation status had a certain relationship with the expression of some common immunohistochemical markers. This study provides more data support for clinical research on *KRAS*/*NRAS*/*BRAF* mutation in CRCs or gastric cancers. In the context of precision medicine, more precise classification of genetic profile should be implemented to enhance the clinical experience. Our study suggested that, combining genetic mutations with immunohistochemical phenotypes could help doctors to formulate cancer treatment strategies more accurately with combining chemotherapy, immunotherapy, and targeted therapy. However, the specific mechanism and clinical significance of the relationship between *KRAS*/*NRAS*/*BRAF* mutation and IHC status still need further experiments to confirm.
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The representative HE and IHC images for the markers.
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Immunohistochemistry characteristics according to KRAS/NRAS/BRAF gene mutation status in colon cancer.
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Immunohistochemistry characteristics according to KRAS/NRAS/BRAF gene mutation status in rectal cancer.
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